Cyclo Therapeutics, a Subsidiary of Rafael Holdings, to Present Research on Niemann-Pick Disease at ICIEM 2025
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, will present research on Niemann-Pick Disease at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. The presentations will include an oral discussion on the efficacy and safety of Hydroxypropyl-beta-cyclodextrin and a poster on open-label treatment in young patients.
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, has had two abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan. These presentations will focus on the use of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1. An oral presentation by Dr. Caroline Hastings will discuss the long-term efficacy and safety of Hydroxypropyl-beta-cyclodextrin, while a poster presentation by Dr. Orna Staretz Chacham will cover open-label treatment in young patients under the TransportNPC Sub-Study. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rafael Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518663-en) on August 27, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
